Company Overview More
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
CEO: Mohanty, Aditya P.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > PROG Progenity > Key Indicators
PROG Progenity
3.640-0.110-2.93%
Post Mkt Price
3.540-0.1-2.75%
YOY
Do not show
Hide blank lines
(Q3)2021/09/30(Q2)2021/06/30(Q1)2021/03/31(FY)2020/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- -- -- -- 69.23% 43.2326 322.52% 66.0889
Receivable Turnover(T)
63.18% 9.7861 51.28% 7.7146 -21.51% 5.6863 -64.27% 4.2622
Inventory Turnover(T)
-- -- -- -- -22.5% 7.9704 -25.51% 8.0699
Fixed Assets Turnover(T)
45.27% 7.2699 51.59% 7.0704 -30.1% 4.8812 -52.22% 4.406
Total Asset Rate(T)
2.65% 0.6909 24.35% 0.4892 -32.95% 0.6848 -56.05% 0.5802
ROA
-105.4% -211.752% -63.08% -152.361% -40.06% -173.598% -10.89% -150.524%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-19.7% -24.463% 27.68% -24.672% -191.8% -8.640% -185.18% -25.729%
Operating Margin
-17.42% -281.165% -1.77% -281.778% -52.95% -230.347% -169.9% -262.657%
Net Margin
-100.09% -306.474% -31.15% -311.421% -108.88% -253.512% -152.34% -259.438%
EBITDA Margin
-11.89% -2.5791% 4.98% -2.5441% -40.65% -2.0339% -176.57% -2.5585%
R & D Expense Ratio
1.8% 64.640% -12.46% 65.840% 12.06% 58.740% 45.92% 64.250%
Sales Expense Ratio
4.73% 69.970% -6.16% 71.410% 27.04% 64.750% 74.01% 71.170%
Administration Expense Rate
37.64% 122.090% 31.08% 119.860% 73.47% 98.220% 138.34% 101.510%
Financial Health Ratios
Current Ratio
-15.48% 0.9002 -20.84% 1.335 12% 1.2637 133.68% 1.7385
Quick Ratio
-35.44% 0.5428 -45.2% 0.8295 10.98% 0.9803 158.91% 1.4416
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%